Oncology & Cancer

Study supports minimal residual disease as end point in myeloma

(HealthDay)—For patients with newly diagnosed multiple myeloma (MM), minimal residual disease (MRD)-negative status is associated with improved survival, according to a meta-analysis published online Sept. 15 in JAMA Oncology.

Oncology & Cancer

New study shows blood test detected cancer metastasis

Researchers from the University Göttingen Institute of Veterinary Medicine and Chronix Biomedical have published a new study exploring the genetic hallmarks of canine mammary cancer. Appearing in the peer-reviewed journal ...

Oncology & Cancer

Obese youths with leukemia more likely to have persistent disease

Obese youths with acute lymphoblastic leukemia (ALL) are known to have worse outcomes than their lean counterparts. To find out why, investigators at Children's Hospital Los Angeles studied patients who were obese at the ...

Oncology & Cancer

Minimal residual disease alone not predictive in T-cell leukemia

Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer. This disease includes two subtypes, B-cell and T-cell leukemia, depending upon the type of white blood cell where the leukemia originates. For B-cell ...

page 1 from 3